Induced Reactivity of Intestinal CD4+ T Cells with an Epithelial Cell Lectin, Galectin-4, Contributes to Exacerbation of Intestinal Inflammation  by Hokama, Akira et al.
Immunity, Vol. 20, 681–693, June, 2004, Copyright 2004 by Cell Press
Induced Reactivity of Intestinal CD4 T Cells with
an Epithelial Cell Lectin, Galectin-4, Contributes
to Exacerbation of Intestinal Inflammation
gens that are recognized by autoantibodies in these
disorders and several animal models of IBD are involved
in generation and/or enhancement of the dysregulated
mucosal immune response (Targan, 1998).
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immunogenic antigens that elicit cellular as well as hu-3Center for the Study of Inflammatory
Bowel Disease moral immunity (Sahin et al., 1995; Jager et al., 1998).
Among the animal models of IBD, the intestinal inflam-Massachusetts General Hospital
4Division of Gastroenterology mation associated with T cell receptor  knockout
(TCRKO) mice shares a number of features with humanBrigham and Women’s Hospital
5Division of Immunology UC, including an increased production of autoantibodies
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Importantly, B cells and autoantibodies in TCRKO miceHarvard Medical School
Boston, Massachusetts 02114 are involved in the regulation of this inflammation as
indicated by the development of much more severe in-
testinal inflammation in the B cell-deficient TCR double
knockout (DKO) mice compared to TCRKO miceSummary
(Mizoguchi et al., 1997a, 2002a). Therefore, SEREX using
autoantibodies present in the TCRKO mice has theInflammatory bowel disease is an immune-mediated
intestinal inflammatory condition that is associated ability to provide useful tools in the identification of CEC-
derived antigens, which may have a role in the pathogen-with an increase in autoantibodies that bind to epithe-
lial cells. However, it is unknown whether the epithelial esis of this type of intestinal inflammation (Targan, 1998).
By using SEREX combined with an additional screen-cell-derived products that are recognized by such
autoantibodies are involved in the pathogenic process. ing approach utilizing cytokine production, we herein
identify a CEC-derived lectin, galectin-4, as a patho-Through a combined antigen-screening approach uti-
lizing humoral and cellular immune responses, we genic mediator that specifically stimulates CD4 T cells
by direct interaction with the immunological synapse toidentify herein an epithelial lectin, galectin-4, that spe-
cifically stimulates IL-6 production by CD4 T cells. enhance production of IL-6, which contributes to exac-
erbation of intestinal inflammation. Importantly, the re-Interestingly, the reactivity of CD4T cells to galectin-4
is precisely elicited under intestinal inflammatory con- activity of CD4 T cells to galectin-4 is only elicited
under inflammatory condition. These results provide anditions. The galectin-4-mediated production of IL-6
is MHC class II independent and induced by PKC- insight into the biological role of an endogenous lectin
under inflammatory condition.associated pathway through the immunological syn-
apse. The galectin-4-mediated stimulation of CD4
T cells is shown to exacerbate chronic colitis and delay Results
the recovery from acute intestinal injury. These studies
identify the presence of an immunogenic, endogenous Screening Approach Utilizing Humoral
lectin in the intestine and dissect the biological role and Cellular Immune Responses
of lectin/CD4 T cell interactions under inflammatory As first round screening to detect CEC proteins that
conditions. are recognized by autoantibodies, we used a modified
SEREX in which Uni-ZAP cDNA libraries generated from
Introduction CEC of TCRKO mice were screened by purified immu-
noglobulins from TCRKO mice with colitis (Figure 1A).
Inflammatory bowel disease (IBD), which is character- After screening of 1.2  106 plaques, 112 positive
ized by two forms of intestinal inflammation, ulcerative plaques were obtained. DNA sequence analysis showed
colitis (UC) and Crohn’s disease (CD), is a group of that the proteins carried by these plaques include un-
chronic, relapsing, and remitting inflammatory condi- known molecules (39/112), galectin-4 (21/112), H2-M 
tions that affect individuals throughout life (Podolsky, 2 chain (13/112), galectin-3 (9/112), mitochondria-asso-
2002). Accumulating evidence has demonstrated that ciated proteins (7/112), elongation factor 2 (5/112), 
dysregulated host/microbial interactions are required spectrin (3/112), transferrin receptor (3/112), and others
for the initiation of the intestinal inflammation (Bhan et (1 or 2/112). The positive clones obtained from the first
al., 1999; Strober et al., 2002). However, it remains un- round of screening were subcloned into the pGEX vector
clear whether the intestinal epithelial cell-derived anti- to generate glutathione S-transferase (GST) fusion pro-
teins, which were subjected to a second round of
screening for the identification of CEC proteins con-*Correspondence: amizoguchi@partners.org
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Figure 1. Identification of Galectin-4 as an Immune Stimulator
(A) The screening procedure composed of two steps utilizing humoral and cellular immune response is summarized (the details are described
in the Experimental Procedures).
(B) After affinity purification, recombinant galectin-4 (G4) and galectin-3 (G3) were separated from the GST moiety by using PreScission
protease and subjected to SDS-PAGE followed by Coomassie staining.
(C) MLN and colonic LP cells (2  105) from diseased DKO mice were cultured with galectin-4 (closed circles) or galectin-3 (closed squares)
for 72 hr, and the culture supernatants subjected to ELISA for detection of IL-6, IL-4, IFN-, and IL-12p40. The data are representative of four
individual experiments.
(D) Total RNA was obtained from the MLN cells cultured without (lane 1) or with 40 g/ml of galectin-4 (lane 2) or galectin-3 (lane 3), and 10
g RNA was subjected to RPA. The data are representative of two individual experiments.
taining immunogenic activity. After affinity purification mouse galectin-4 [37 to 981] was identified (see the
Supplemental Data available at http://www.immunity.with glutathione Sepharose, the recombinant proteins
encoded by positive clones were separated from the com/cgi/content/full/20/6/681/DC1; the information is
available by accessing Gene Bank AF510729). Interest-GST moiety by PreScission protease and further purified
by removing potential contamination with endotoxin us- ingly, the first round of screening also identified a posi-
tive clone carrying the full-length cDNA encoding an-ing endotoxin-removal column. After culture of mesen-
teric lymph node (MLN) and colonic lamina propria (LP) other galectin family member, galectin-3. However, in
contrast to galectin-4, galectin-3 did not induce IL-6cells from diseased DKO mice with the recombinant
proteins for 3 days, the culture supernatants were sub- production (Figures 1B and 1C). In addition, RNase pro-
tection assay (RPA) confirmed that IL-6 mRNA expres-jected to ELISA for detection of IL-4, IFN-, IL-6, and
IL-12p40. sion was upregulated in MLN cells of DKO mice after
stimulation with galectin-4 but not galectin-3 (Figure 1D).
Identification of Galectin-4 as an Immune Stimulator
The screening identified a 33 kDa recombinant protein Galectin-4 Stimulates IL-6 Production by CD4 T Cells
To identify the cell type which produced IL-6 in responsethat stimulated production of IL-6 but not other cyto-
kines tested (Figures 1B and 1C). DNA sequence analy- to galectin-4, CD4 T cells (a pathogenic subset),
TCR T cells (a major T cell subset in DKO mice),sis showed that the cDNA encoding this protein was
identical to murine galectin-4. Since only a partial cDNA CD11c cells (dendritic cells), and cells attached to plas-
tic plates (macrophages and fibloblasts) from the co-sequence [62 to 964] for mouse galectin-4 has been
described (Gitt et al., 1998), a full-length cDNA encoding lonic LP of DKO mice with colitis were purified. In
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2A). Of note, addition of an anti-MHC-class II mAb (10
g/ml) into the culture did not affect the production of
IL-6 by galectin-4-stimulated CD4 T cells (Figure 2B).
To examine whether the increased IL-6 production re-
sulted from galectin-4-mediated expansion of CD4
T cells, in vitro [3H]-thymidine incorporation was as-
sessed. Galectin-4 failed to induce proliferation of co-
lonic LP CD4 T cells (Figure 2C). In addition, galectin-4
did not directly enhance the survival of CD4 T cells
in vitro during a 48 hr period of observation (Figure 2D).
Galectin-4-Mediated IL-6 Production Is Observed
under Inflammatory but Not
Noninflammatory Conditions
To examine whether galectin-4-mediated IL-6 produc-
tion by CD4 T cells is a common feature of DKO
mice, CD4 T cells were purified from colonic LP of
these mice without or with mild, moderate, or severe
colitis and subjected to ELISA after 3 days of culture
(Figure 3A). In response to galectin-4, a further increase
in IL-6 production was observed by CD4 T cells from
severely affected colon compared to mildly diseased
Figure 2. Galectin-4 Specifically Induces IL-6 Production by CD4 colon. Of note, galectin-4 did not stimulate IL-6 produc-
T Cells tion by colonic LP CD4 T cells from DKO mice with-
(A) Colonic LP cells from DKO mice with moderate colitis were out colitis. Furthermore, in DKO mice with colitis,
incubated with either FITC-conjugated anti-CD4 (RM4-5), anti-TCR galectin-4-mediated IL-6 production was significantly
(GL3), or anti-CD11c (HL3) mAbs and the stained cells positively
more apparent from CD4 T cells of colon and MLNsorted after incubation with anti-FITC magnetic beads under a mag-
compared to those of spleen, small intestine, and axillarynetic cell sorting (MACS) system. The purity of each subset was
lymph nodes (Figure 3B). Like the colon and MLN, the	91%. Colonic LP cells were cultured on plastic plate for 2 hr and
the adherent cells harvested by using trypsin-EDTA and used as majority of CD4 T cells in the small intestine and axillary
Mφ-enriched population. B cells (B220 	 84%) were enriched from lymph nodes were characterized by a memory pheno-
colonic LP of TCRKO mice with colitis by depleting CD3
 (145- type as determined by the expression of CD62L, CD69,
2C11) NK (DX-5) CD11b (M1/7) and CD11c (HL3) cells under a
and CD45RB (data not shown).MACS system. For 72 hr, 1  105 cells were cultured without (open
The CD4T cells present in TCRKO mice are a uniquebars) or with 20 g/ml galectin-4 (black bars) or galectin-3 (gray
subset (TCR), which expresses a TCR chain with-bars) and the culture supernatants subjected to ELISA for detection
of IL-6. The data represent an average  SEM of three to seven out a TCR chain (Mombaerts et al., 1993; Bhan et al.,
individual experiments. 1999). The colitis observed in this mouse model is medi-
(B) CD4 cells (1  105; purity 	96%) purified from colonic LP of ated by a Th2-pathway (Mizoguchi et al., 1999; Iijima et
diseased DKO mice were cultured with galectin-4 alone (solid
al., 1999). Therefore, to define whether the response ofbar) or galectin-4 plus 10 g/ml of anti-Iab mAb (open bar) and the
CD4 T cells to galectin-4 reflects a unique feature ofculture supernatants subjected to ELISA for detection of IL-6.
CD4TCR T cells in TCRKO mice, colonic CD4(C) For 72 hr, 1 105 purified colonic LP CD4 T cells from diseased
DKO mice were cultured without (triangles) or with (closed circles) TCR T cells were purified from two additional colitis
various concentrations of galectin-4. As a positive control (open models. These included (1) a well-established Th1-medi-
bar), the cells were stimulated with plate-coated anti-CD3
 mAb (10 ated colitis model (CD45RB model), which is induced
g/ml, 145-2C11) plus soluble anti-CD28 mAb (1 g/ml, 37.51). After
by transfer of splenic CD4 CD45RBhigh T cells from wild-a pulse with 1 mCi of [3H] thymidine for 16 hr, thymidine-uptake was
type (wt) mice into an immunodeficient host (Powriemeasured. The data are representative of three individual experi-
1995; Read et al., 2000), and (2) an acute colitis modelments.
(D) For 48 hr, 1 105 purified colonic LP CD4 T cells from diseased (dextran sodium sulfate [DSS] model) in which the colitis
DKO mice were cultured without (W/O) or with 40g/ml galectin-4 is induced by oral administration of DSS (Elson et al.,
(G4) or plate-coated anti-CD3
 mAb plus soluble anti-CD28 mAb 1995; Kabashima et al., 2002). The purified CD4 T cells
(3/28). The number of viable cells was counted by using trypan blue
from the colonic LP of these models were cultured withdye exclusion test. Survival rate represents the percentage (viable
or without galectin-4 or galectin-3 and the culture super-cell number after 48 hr culture/cell number applied to the culture).
natants subjected to ELISA. Like DKO mice with coli-The results represent an average  SEM of five individual experi-
ments. tis, galectin-4 also stimulated IL-6 production by the
colonic LP CD4 T cells from the CD45RB and DSS
models (Figure 3C). In contrast, the CD4 T cells from
normal colon of wt mice did not produce IL-6 after theaddition, B cells were enriched from the colonic LP of
diseased TCRKO mice by depleting CD3NKCD11b stimulation with galectin-4. These findings indicate that
the ability of CD4 T cells to produce IL-6 in responseand CD11c cells. These cell types were stimulated with
or without galectin-4 or galectin-3 for 72 hr, and the to galectin-4 is precisely elicited under intestinal inflam-
matory conditions mediated by distinct mechanismsculture supernatants were subjected to ELISA. Galectin-4
but not galectin-3 selectively stimulated IL-6 production and further enhanced depending upon the degree of in-
flammation.by CD4T cells but not the other cell types tested (Figure
Immunity
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Figure 3. Reactivity of CD4T Cells to Galec-
tin-4 Is Elicited under Inflammatory Condi-
tions
For 72 hr, 1  105 purified cells were cultured
without (open bars) or with 20 g/ml
galectin-4 (black bars) or galectin-3 (gray
bars) and the culture supernatants subjected
to ELISA for detection of IL-6.
(A) CD4 T cells (purity 	97%) were purified
from colonic LP of DKO mice without or
with mild, moderate, or severe colitis. The
data present are representative of four to
seven individual experiments.
(B) CD4 T cells (purity 	93%) were purified
from colonic LP, MLN, small intestinal LP (SI),
spleen (SP), and axillary LN of the same indi-
vidual DKO mice with moderate colitis. The
data presented are representative of three
individual experiments.
(C) CD4 T cells (purity 	94%) were purified
from colonic LP of wt, diseased TCRKO
mice, CD45RB model (8 weeks after the
transfer of wt splenic CD4 CD45RBhigh cells
into RAG-1 KO mice), or DSS model (4 days
after 3.5% DSS administration into wt mice).
The data presented are representative of
three to four individual experiments.
Expression of Galectin-4 in Colonic Epithelial Cells T cells was analyzed by flow cytometry using Alexa Fluor
488-labeled recombinant galectin-4. As predicted, moreGalectin-4 is only expressed in epithelial cells of the
digestive tract (Gitt et al., 1998) and secreted through intense binding of galectin-4 but not galectin-3 was ob-
an unorthodox secretory pathway from both the apical served on CD4 T cells from diseased colon compared
and basolateral membranes of epithelial cells (Hughes, to normal colon (Figure 5A). Interestingly, fluorescence
1999). To further confirm this observation, a monoclonal microscopic analysis showed a patchy binding pattern
antibody (mAb, IgG1) specific for mouse galectin-4 was of galectin-4 to CD4 T cells from normal colon (Figure
generated by fusing B cells from diseased TCRKO mice 5B). Consistent with the flow cytometry results (Figure
with NS-1 myeloma cell line as previously described 5A), the patchy binding observed was much more in-
(Mizoguchi et al., 1997a). Western blot analysis con- tense on CD4 T cells from diseased colon (Figure 5C).
firmed that this mAb recognized mouse recombinant Other galectin members, such as galectin-1 and -3,
galectin-4 (Figure 4A) and an identical molecular weight have been demonstrated to interact with the immuno-
protein present in the lysate obtained from the CEC of logical synapse (IS) (Chung et al., 2000; Demetriou et
DKO mice (Figure 4B). Immunohistochemical analysis al., 2001). In addition, galectin-4 has recently been dem-
using this mAb showed that galectin-4 expression was onstrated to function as a lipid raft stabilizer, the creator
detectable in CEC (Figure 4C). Since galectin-4 induced of “superrafts” on small intestinal epithelial cells (Brac-
IL-6 upregulation of colonic CD4 T cells, we postulated cia et al., 2003). Furthermore, the binding pattern ob-
that galectin-4 expression in the CEC is induced or served for galectin-4 on colonic LP CD4 T cells was
upregulated during intestinal inflammation. However, unique (Figure 5B). Therefore, to test whether galectin-4
RT-PCR showed that there was no significant difference also interacts with IS on colonic LP CD4 T cells, colo-
in galectin-4 mRNA expression in the CEC among vari- calization of galectin-4 with lipid rafts that accumulate
ous mouse groups (DKO mice, CD45RB model, DSS- in the central zone of IS maintained for several hours
colitis model [4 days after initiation of DSS treatment], (Xavier et al., 1998; Grakoui et al., 1999; Dupre et al.,
and wt mice) (Figure 4D). In addition, real-time PCR 2002; Burack et al., 2002) was analyzed by confocal
confirmed that there was no statistically significant dif- microscopy. Staining using Alexa Fluor 594-labeled
ference in the expression of galectin-4 mRNA in the CEC cholera toxin (red fluorescence), which can recognize
among these mouse groups (Figure 4E). Furthermore, ganglioside GM1 enriched in lipid rafts, showed that
Western blot analysis using anti-galectin-4 antibodies lipid rafts are present diffusely throughout the cell mem-
confirmed that there was no significant difference in brane as well as in focal accumulations on the cell sur-
galectin-4 expression in freshly isolated CECs among face of CD4 T cells from diseased colon of DKO
these mouse groups (Figure 4F). mice and DSS model (Figure 5D). Of note, the Alexa Fluor
488-labeled galectin-4 (green fluorescence) specifically
bound to the lipid raft-accumulating regions. The IS isGalectin-4 Binds to the Immunological Synapse
on CD4 T Cells generated in the contact surface on T cells to antigen-
presenting cells (APC) and maintained for several hoursGalectin-4-mediated IL-6 production of CD4 T cells
was MHC class II independent, as shown above. There- (Grakoui et al., 1999; Dupre et al., 2002; Burack et al.,
2002). Therefore, to further confirm the interaction offore, it was further postulated that galectin-4 may di-
rectly bind to the cell surface of CD4T cells. To examine galectin-4 with the IS, purified colonic LP CD4 T cells
were cocultured with CD11c cells in the presence ofthis possibility, the ability of galectin-4 to bind to CD4
Galectin-4 in Inflammation
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Figure 4. Galectin-4 Expression in CEC
(A and B) Recombinant galectin-4 (A) and pro-
tein lysate (10 g) from the CEC of DKO
mice (B) were subjected to SDS-PAGE fol-
lowed by transfer to ECL membrane. The
membrane was incubated with control mouse
IgG (Cont.) or mouse anti-mouse galectin-4
mAb (@G4). After incubation with HRP-anti-
mouse IgG, the band was detected by using
ECL detection system.
(C) Immunohistochemical analysis shows the
positive staining of anti-galectin-4 mAb in the
epithelial cells of colon from wt mice.
(D) RT-PCR shows there is no significant dif-
ference of galectin-4 and -actin mRNA ex-
pression in the freshly isolated CEC between
diseased colon (DKO mice and CD45RB
and DSS models) and normal colon (wt mice).
(E) Real-time PCR shows there is no statisti-
cally significant difference of galectin-4 and
-actin mRNA expressions in the freshly iso-
lated CEC between diseased colon (TCRKO
[n  5] and DKO mice [n  8]; CD45RB
[n  4] and DSS models [n  5]) and normal
colon (wt mice [n 6]). No detectable fluores-
cence signal was observed in the negative
control reactions omitting the cDNA for
-actin (data not shown) and galectin-4
(right).
(F) Lysates (10 g) obtained from freshly iso-
lated CEC of wt mice and diseased DKO
mice and CD45RB models were immunoblotted with affinity peptide-purified rabbit anti-galectin-4 antibody recognizing DKVVFKTMQSGQ
WGKEEKC (Affinity BioReagents) or goat anti-actin antibody (Santa Cruz) followed by incubation with HRP-anti-rabbit or goat IgG (Pierce)
and developed by an ECL system.
cecal bacterial antigens (20 g/ml) and subjected to istration of 4% DSS. CD4 T cells were then purified
from the colonic LP 5 days after the induction and cul-staining with Alexa Fluor 488-labeled galectin-4. An in-
tensified galectin-4 staining pattern was observed at the tured with or without recombinant galectin-4. The galec-
tin-4 failed to stimulate the PKC-deficient CD4 T cellscontact region between the two cells (Figure 5E). These
results indicate that galectin-4 can interact with the IS to produce IL-6 (Figure 5G). In contrast, galectin-4 dose
dependently upregulated IL-6 production by the colonicon colonic LP CD4 T cells and the binding is intensified
under inflammatory conditions. LP CD4 T cells from DSS-treated wt control mice. Im-
portantly, more rapid recovery from DSS-induced acute
colitis was observed in the PKC/ mice compared toProtein Kinase C  Is Required for Galectin-4-
Mediated IL-6 Upregulation the PKC/ control mice after the cessation of DSS
intake for 5 days (Figure 5H). These results obtainedPKC, a Ca2-independent PKC member, is selectively
translocated to the central region of the IS and required from in vitro and in vivo studies indicate that PKC-
associated signaling cascades play a crucial role in thefor the activation of the IS-mediated signaling cascades
(Sun et al., 2000; Arendt et al., 2002; Isakov and Altman, upregulation of IL-6 production by galectin-4, sug-
gesting a unique signaling pathway distinct from the2002; Pfeifhofer et al., 2003). Therefore, to examine
whether PKC is required for the galectin-4-mediated MAP p38 kinase-associated cascade.
upregulation of IL-6 production, purified colonic LP
CD4 T cells were pretreated with 20 M rottlerin, an Endogenous Galectin-4 Contributes to Exacerbation
of a Chronic Colitisinhibitor of Ca2-independent PKC (Isakov and Altman,
2002), prior to culture with galectin-4. Pretreatment with To examine whether endogenous galectin-4 contributes
to exacerbation of colitis, an anti-galectin-4 mAb wasthis inhibitor significantly decreased the induction of
IL-6 production by galectin-4 (p  0.001, Figure 5F). In administrated intraperitoneally into DKO mice that
had developed moderate intestinal inflammation. Forcontrast, pretreatment of the CD4 T cells with 0.5 M
Go6970 (inhibitor of Ca2-dependent PKCs) or 10 M this, laparotomy at 15 weeks of age was performed to
confirm the presence of moderate colitis as judged byKT5720 (inhibitor of PKA) did not affect the galectin-4-
induced IL-6 production. In addition, an inhibitor (40 increased colonic diameter of the distal colon (Figures
6A and 6B). Administration of the anti-galectin-4 mAbM SB203580) of mitogen-activated protein (MAP) p38
kinase involved in activation of IL-6 production (Beyaert (1.5 mg, every week) was then started 10 days after the
laparotomy and the mice sacrificed 44 days after theet al., 1996) failed to suppress the galectin-4-mediated
upregulation of IL-6. laparotomy. Of note, the administration of the anti-
galectin-4 mAb led to a significant reduction in the co-To further confirm the in vitro observation, colitis was
induced in PKCKO mice (Sun et al., 2000) by the admin- lonic diameter in DKO mice (Figures 6A and 6C). In
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Figure 5. Galectin-4 Interacts with IS on
CD4 T Cells
(A) Colonic LP cells from wt (black line) and
diseased DKO (red line) mice were incu-
bated without (green line) or with Alexa Fluor
488-labeled recombinant galectin-4 (upper
panel) or galectin-3 (lower panel), followed by
staining with PE-anti-CD4 mAb and PerCP-
anti-TCR mAb, and subjected to flow cyto-
metric analysis. The expression of Alexa Fluor
488 on the gated CD4TCR cells is shown.
The data are representative of three individ-
ual experiments.
(B and C) Colonic LP CD4 T cells from wt
(B) and diseased DKO mice (C) were incu-
bated with biotinylated anti-CD4 mAb fol-
lowed by incubation with streptavidin micro-
beads and purified under MACS. After
incubation of the cells with Alexa Fluor 488-
labeled recombinant galectin-4, the cells
were subjected to fluorescence microscopic
analysis. The data are representative of three
individual experiments.
(D) Colonic LP CD4 T cells from diseased
DKO mice (upper panels) and DSS model
(lower panels) were incubated with biotinyl-
ated anti-CD4 mAb followed by incubation
with streptavidin microbeads and purified un-
der MACS. After staining the purified cells
with Fluor 594-labeled cholera toxin (red
fluorescence, left panels) and Alexa Fluor
488-labeled recombinant galectin-4 (green
fluorescence, middle panels), the cells were
subjected to confocal microscopic analysis.
Right panels show the overlay image.
(E) CD11C and CD4 cells were separately
purified from colonic LP of diseased DKO
mice. A mix of these cells was incubated with
20 g/ml enteric bacterial antigens for 6 hr on
a poly-L-lysine-coated plate and fixed. After
staining with Alexa Fluor 488-labeled recom-
binant galectin-4, the cells were subjected to
fluorescence microscopic analysis.
(F) Purified colonic LP CD4 T cells from dis-
eased DKO mice were pretreated with op-
timized dose of inhibitors at 37C for 30 min
or 1 hr. After washing, the cells were cultured
with 40 g/ml galectin-4 for 72 hr, and the
culture supernatants were subjected to
ELISA for the detection of IL-6. The data rep-
resent an averageSEM of five individual ex-
periments.
(G) Colitis was induced in PKC/ (open cir-
cles) and PKC/ (solid circles) mice by oral
administration of 4% DSS for 5 days, and the
colonic LP CD4 T cells were purified from
the colonic LP. After culture of these cells
with various concentration of galectin-4 (0, 2,
5, 20 g/ml) for 72 hr, the culture supernatants were subjected to ELISA for the detection of IL-6. The data are representative of four
individual experiments.
(H) Colitis was induced in PKC/ (open circles, n  18) and PKC/ (solid circles, n  15) mice by adding 4% DSS in drinking water. The
treatment was terminated day 5 by changing the DSS water to normal drinking water. The body weight changes (%) compared to the initial
body weight (day 0) are shown. “*” represents p  0.005.
distinct contrast, the colonic diameter gradually in- not control mAb led to a decrease in the absolute num-
bers of colonic LP CD4 T cells (Figure 6E). Furthermore,creased in DKO mice treated with the control mAb
(Figures 6B and 6C). Histological analysis also con- RT-PCR showed downregulation of IL-6 mRNA expres-
sion in the purified colonic LP CD4 T cells from DKOfirmed that the disease score was significantly (p 
0.005) reduced in the DKO mice treated with the anti- mice treated with the anti-galectin-4 mAb compared to
the control mAb-treated mice (Figure 6F). Quantitativegalectin-4 mAb compared to the control mAb (Figure
6D). In addition, treatment with the anti-galectin-4 but PCR analysis revealed that the anti-galectin-4 mAb
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treatment led to 2.9 times decrease of IL-6 mRNA ex- DSS-treated mice injected with PBS or control mAb after
the cessation of DSS intake (Figure 7A). Of note, morepressions in the colonic LP CD4 T cells (see Supple-
rapid recovery from the acute inflammation was ob-mental Data on Immunity’s website). Moreover, enzyme-
served in the DSS-treated mice that received the anti-linked immunospot (ELISPOT) assays also revealed that
galectin-4 mAb. Indeed, much milder intestinal inflam-the numbers of IL-6-producing CD4 T cells in the co-
mation as judged by the disease score (a combinationlonic LP of anti-galectin-4 mAb-treated DKO mice
of gross appearance, colon length, occult blood, andwas significantly lower (p 0.05) than that of the control
histological scores) was observed in DSS-treated micemAb-treated DKO mice (Figures 6G and 6H). These
that received the anti-galectin-4 mAb (Figures 7B anddata demonstrate that endogenous galectin-4 contrib-
7D) compared to the control mAb (Figures 7C and 7D).utes to the exacerbation of chronic colitis in DKO
These findings indicate that endogenous galectin-4mice by stimulating colonic LP CD4 T cells to further
functions to prevent the recovery from acute intestinalproduce IL-6.
injury.IL-6 has been demonstrated to play a crucial role
The results shown in Figure 4 demonstrated that thein the pathogenesis of colitis by the enhancement of
production of galectin-4 per epithelial cell is not alteredpathogenic T cell survival through the activation of signal
under inflammatory conditions. However, elongated epi-transduce and activator of transcription (STAT) 3, bcl-2,
thelial crypts indicating an increased number of CECsand bcl-XL (Atreya et al., 2000). Indeed, downregulation
per colon is a common feature in chronic colitis (Mizo-of STAT-3 activation in the colon was observed in -
guchi et al., 2003). Therefore, the increased CEC massDKO mice treated with anti-galectin-4 mAb compared
may subsequently result in an increase in the totalto control mAb (Figure 6I). In addition, quantitative PCR
amount of circulating galectin-4, which can cause fur-(QPCR) analysis demonstrated that the anti-galectin-4
ther activation of pathogenic CD4 T cells. To investi-mAb treatment led to downregulation of bcl-2 and bcl-
gate this issue, a recombinant galectin-4 was adminis-XL expressions in the purified colonic LP CD4 T cells
trated intravenously into the DSS model that isof DKO mice (Figure 6J). Of note, the treatment in-
characterized by a loss rather than an elongation ofduced a significant increase (p 0.001) in the proportion
epithelial crypts during the acute phase. Induction ofof apoptotic cells in the colonic LP CD4 T cell popula-
this type of colitis was performed as described above.tion (Figure 6K): the proportions of apoptotic cells in the
Galectin-4 (2 mg), galectin-3 (2 mg), or PBS was injectedCD4 T cells were 5.4% 1.4% in DKO mice, 6.9%
twice into the DSS-treated mice on day 4 and 6 after the1.3% in control mAb-treated DKO mice, and 14.3%
induction of colitis. Gradual weight gain was observed in1.9% in anti-galectin-4 mAb-treated DKO mice.
the DSS-treated mice injected with not only PBS butThese findings suggest that, although galectin-4 does
also galectin-3 after the cessation of DSS intake. Innot directly induce the survival of CD4 T cells (Figure
contrast, administration of galectin-4 led to transient2D), the galectin-4 indirectly contributes to the enhance-
weight loss and significant delay of the recovery (Figurement of intestinal CD4 T cell survival in vivo by stimulat-
7E). In addition, much more severe colonic inflammationing IL-6 production.
was observed in DSS-treated mice that received galec-
tin-4 (Figures 7F and 7H) compared to galectin-3 (Fig-
Galectin-4 Leads to Delay in the Recovery
ures 7G and 7H). Furthermore, in comparison to injection
from Acute Inflammation
of PBS or galectin-3, the administration of galectin-4
The disease observed in the majority of colitis model, led to a marked increase in the absolute numbers of
including the DKO mouse model, is progressive after colonic LP CD4 cells and an upregulation of IL-6 ex-
onset. In contrast, the colitis associated with DSS model pression in the colonic LP (Figures 7I and 7J). These
spontaneously recovers after cessation of DSS intake, findings suggest that increased exposure to galectin-4
and the degree of disease can be monitored by the body can further stimulate CD4 T cells to produce IL-6.
weight change (Williama et al., 2002). The development To further examine whether IL-6 is a key factor in-
of DSS colitis is induced by an innate immune response volved in the galectin-4-mediated exacerbation of coli-
(Dieleman et al., 1994). However, after onset, CD4 tis, in vivo neutralization of IL-6 activity by the adminis-
T cell-mediated acquired immune responses are also tration of anti-IL-6 mAbs was performed as previously
involved in the exacerbation and perpetuation of this described (Starnes et al., 1990; Riedemann et al., 2003).
colitis (Kabashima et al., 2002). Therefore, the DSS For this, anti-IL-6 mAbs (0.75 mg) or control rat immuno-
model was used to examine whether galectin-4 contrib- globulins (Igs) were intraperitoneally administrated on
utes to the perpetuation and/or exacerbation of this day 4, 6, and 8 into the 4% DSS-treated mice that re-
colitis by activating CD4 T cells. For this, wt mice were ceived recombinant galectin-4 on day 4 and 6. The ad-
treated with 3.5% DSS in drinking water for 5 days fol- ministration of anti-IL-6 mAsb but not control rat Igs
lowed by termination of the DSS administration by significantly inhibited the galectin-4-mediated delay of
changing the DSS water to normal drinking water. To the recovery from acute colitis (Figure 7K). In addition,
avoid the influence of variations in the degree of colonic the disease score was significantly lower in DSS-treated
inflammation induced by innate immune responses, ad- mice administrated with galectin-4 plus anti-IL-6 mAbs
ministration of an anti-galectin-4 (1.5 mg) or control mAb (the score was 5.7  0.8) compared to those with galec-
(1.5 mg) was performed on selected female mice that tin-4 plus control Igs (8.3  1.5). Interestingly, the anti-
exhibited 90%–93% of body weight loss on day 4. The IL-6 mAb treatment led to a marked reduction of the
mAbs were then injected intraperitoneally three times proportion of CD4 T cells in the total colonic LP cells
on days 4, 5, and 6. As previously described (Williama (Figure 7L) as well as the absolute numbers (the absolute
numbers of colonic LP CD4 T cells were 4.0  0.9 et al., 2002), a gradual weight gain was observed in the
Immunity
688
Figure 6. Endogenous Galectin-4 Contributes to the Exacerbation of Chronic Colitis
(A–C) The diameter of the distal colon was measured by opening the abdomen of anesthetized DKO mice at 15 weeks of age (Be). Ten
days after the operation, anti-galectin-4 mAb (1.5 mg) (A) or control mAb (1.5 mg) (B) recognizing LP stromal cells (Mizoguchi et al., 1996)
was intraperitoneally injected into the DKO mice. The injections were performed every week, and the mice were sacrificed 44 days after
the operation (Af). The gross findings of distal colon before (Be) and after (Af) the treatment are shown. The number in each panel represents
the colonic diameter. The results are summarized in (C).
(D) Disease scores of DKO mice treated with anti-galectin-4 mAb (@G4) or control mAb (Cont.) are shown. Each dot represents an
individual mouse.
(E) Absolute numbers of colonic LP CD4 T cells from DKO mice treated with anti-galectin-4 mAb (@G4) or control mAb (Cont.) are shown.
(F) Total RNA were isolated from 3  105 purified colonic LP CD4 T cells from DKO mice treated with anti-galectin-4 mAb (@G4) or control
mAb (Cont.) and subjected to RT-PCR for the detection of IL-6, CD4, and -actin.
(G and H) The purified colonic LP CD4 T cells from DKO mice treated with anti-galectin-4 mAb (@G4) or control mAb (Cont.) were cultured
on an ELISPOT plate coated with anti-IL-6 mAb for 12 hr. After washing, the IL-6-producing cells were detected (G) as previously described
Galectin-4 in Inflammation
689
105 in the anti-IL-6 mAb-treated mice and 6.9 0.7 105 been found to interact with core 1 O-glycan substrates
(Ideo et al., 2002). Functionally, galectin-3, which is ex-in the control Ig-treated mice, p  0.05). These findings
suggest that IL-6 is involved in the galectin-4-mediated pressed by a wide variety of cell types, has been demon-
strated to dampen TCR sensitivity to antigens (Deme-exacerbation of colitis.
triou et al., 2001). Galectin-1, which is also expressed
by a wide variety of cell types and, of note, upregulatedDiscussion
on CD4CD25 regulatory T cells (McHugh et al., 2002),
is able to induce apoptosis of T cells (Perillo et al., 1995).Although autoimmune mechanisms have been impli-
cated in the pathogenesis of IBD (Targan, 1998; Strober The administration of a galectin-1 fusion protein has
recently been demonstrated to suppress intestinal in-et al., 2002), it has not been determined whether CEC-
derived antigens that are recognized by autoantibodies flammation induced by trinitrobenzene sulfonic acid
(TNBS) (Santucci et al., 2003). In contrast, we here dem-are involved in the disease process. We here demon-
strate that a CEC-derived endogenous lectin, galectin-4, onstrate that galectin-4 selectively produced by intesti-
nal epithelial cells (Gitt et al., 1998) acts as a stimulatorpossesses immunogenic activity that specifically stimu-
lates IL-6 production under inflammatory conditions by of mucosal CD4 T cells and contributes to the exacer-
bation of intestinal inflammation. Therefore, it is likelyinteracting with the immunological synapse generated
on colonic LP CD4 T cells leading to exacerbation of that the binding site or the structure of galectins is an
important determinant of galectin-mediated immuneintestinal inflammation.
Some of the oligosaccharide structures in the glycans function (Rabinovich et al., 2002).
Interestingly, reactivity of CD4 T cells to galectin-4associated with receptors on lymphocytes are recog-
nized by specific lectins (Rudd et al., 2001; Lowe, 2001; is elicited under inflammatory conditions. Therefore, it
is possible that a specific receptor that is selectivelyBaum, 2002). Plant-derived lectins, such as concanava-
lin (Con) A, have long been used as surrogates for au- crosslinked by galectin-4 may be expressed on colonic
LP CD4 T cells only under inflammatory conditions.thentic lymphocyte activation stimuli (Rudd et al., 2001;
Lowe, 2001; Baum, 2002). Like exogenous lectins, some However, galectin-4 can bind to the IS on both CD4
T cells from normal and diseased colon albeit the bindingendogenous mammalian lectins also play an important
role in immune responses by crosslinking certain sur- intensity is much higher on diseased CD4 T cells (Fig-
ures 5A and 5C). Therefore, it is more likely that inflam-face glycoreceptors (Rudd et al., 2001; Lowe, 2001; Yeh
et al., 2001; Feinberg et al., 2001; Dahl et al., 2001; Baum, matory condition-mediated glycan structural change
allows intensified binding of galectin-4 by inducing a2002). Galectins belong to the mammalian lectin family
and are classified into 14 members (galectin-1 to galec- further exposure of core 1 O-glycan (ligand of galectin-4)
on IS-associated receptors. This may confer an abilitytin-14). Galectins are characterized by the ability to bind
a lactosamine unit of glycans through preserved carbo- of CD4 T cells to respond to galectin-4. Indeed, glycan
structures are constitutively modified by a large numberhydrate recognition domains (CRD). The 14 galectin
members are structurally subgrouped into three groups: of glycosylation-related enzymes whose expression
pattern in each cell is influenced by several conditions,prototype, chimera type, and tandem-repeat type (Bar-
ondes et al., 1994; Rabinovich et al., 2002). The proto- including inflammation (Dell and Morris, 2001; Lowe,
2001; Baum, 2002; Rabinovich et al., 2002). Importantly,type galectins, including galectin-1,-2,-5,-7,-11,-13,
and -14, are noncovalent homodimers composed of two the subsequent glycan structural changes play signifi-
cant roles in several immune responses (Priatel et al.,identical CRDs. Only galectin-3 is the chimera type com-
posed of a CRD linked to a proline-, glycine-, and tyro- 2000; Daniels et al., 2001; Moody et al., 2001; Lowe,
2001; Baum, 2002).sine-rich N-terminal domain. The tandem-repeat type,
including galectin-4, -6, -8, -9, and -12, contain two The galectin-4-mediated IL-6 upregulation is induced
by interacting with the IS. Indeed, PKC, a key signalingdistinct CRDs. Since the CRD of galectins can crosslink
glycosylation sites of some surface glycoreceptors, the molecule associated with the IS (Arendt et al., 2002;
Isakov and Altman, 2002), is required for the galectin-4-galectin family effectively participates in immune re-
sponses (Lowe, 2001; Baum, 2002). Interestingly, the mediated IL-6 upregulation. In contrast, the MAPp38-
associated cascade involved in proinflammatory cyto-binding sites of galectins differ depending upon the type
of galectins; for example, galectin-1 binds to core 2 kine-inducing IL-6 production (Beyaert et al., 1996;
Dinarello, 1996) is not necessary for the upregulationO-glycan substrates (Perillo et al., 1995; Lowe, 2001),
whereas galectin-3 binds to complex N-glycans (Deme- observed. Therefore, it is possible that a unique cascade
associated with PKC may be utilized for galectin-4-triou et al., 2001; Lowe, 2001). Recently, galectin-4 has
(Mizoguchi et al., 1996). The numbers of spot-forming cells (SFC) for IL-6 per 1  105 CD4 T cells are summarized in (H) in which each dot
represents an individual mouse.
(I) Proteins extracted from the colonic mucosa of DKO mice treated without (W/O, n  3) or with anti-galectin-4 mAb (@G4, n  4) or control
mAb (Cont., n  4) were immunoblotted with anti-phospho-STAT3 (PY-STAT3) Ab (Cell Signaling Technology). After stripping PY-STAT Ab,
the membrane was reprobed with anti-STAT3 Ab (Santa Cruz). The averages ratio calculated by band density of phosphorylated STAT3/
density of STAT3 were 0.326  0.063 in the W/O, 0.189  0.052 in the @G4, and 0.349  0.031 in the control.
(J) QPCR analysis was performed using RNA from the purified colonic LP CD4 T cells from wt mice (W) and DKO mice treated with control
mAb (C) or anti-galectin-4 mAb (4). The date represents the average (n  5) of the values of 2CT of bcl2 or bclXL/2CT of -actin.
(K) Colonic LP cells from DKO mice treated with control mAb (Cont.) or anti-galectin-4 mAb (@G4) were stained with FITC-CD4 (RM4.4) mAb
and PE-Annexin V-apoptosis detection kit (Pharmingen) according to the manufacturer’s instruction and subjected to flow cytometric analysis.
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Figure 7. Endogenous Galectin-4 Suppresses the Recovery from Acute Intestinal Injury
(A–D) Colitis was induced in wt female mice by adding 3.5% DSS in drinking water. The treatment was terminated day 5 by changing the DSS
water to normal drinking water. PBS (n  17), 1.5 mg of anti-galectin-4 mAb (G4, n  10), or control mAb (C, n  5) was intraperitoneally
injected three times on day 4, 5, and 6.
(A) The body weight changes (%) compared to the initial body weight (day 0) are shown. *p  0.005, DSS-treated mice administrated with
PBS versus mAb.
(B and C) H & E sections of colon from DSS-treated mice (day 12) with administration of anti-galectin-4 mAb (B) or control mAb (C) are shown.
(D) The disease scores of these mouse groups are summarized.
(E–J) Colitis was induced in wt female mice by adding 3.5% DSS in drinking water. The treatment was terminated day 5 by changing the DSS
water to normal drinking water. Two milligrams of recombinant galectin-4 (G4, n  17), or galectin-3 (G3, n  14) was intravenously injected
twice on day 4 and day 6.
(E) The body weight changes (%) compared to the initial body weight (day 0) are shown. *p  0.005, DSS-treated mice with administration
of PBS versus galectins.
(F and G) H & E sections of colon from DSS-treated mice (day 12) with recombinant galectin-4 (F) or galectin-3 (G) administration are shown.
Severe inflammation characterized by severe cellular infiltration is still persisted in the colon of DSS-treated mice administrated with galectin-4
(F) compared to galectin-3 (G).
(H) The disease scores of these mouse groups are summarized.
(I) Colonic LP cells were isolated from control wt mice (C) and DSS-treated mice with administration of PBS (P), galectin-4 (G4), or galectin-3
(G3), stained with FITC-anti-CD4 mAb and PE-anti-TCR mAb, and subjected to flow cytometric analysis. Each dot represents the absolute
number of CD4 TCR T cells in the colonic LP of individual mouse.
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helper phages in the SOLR strain. Inserted cDNAs were digestedmediated IL-6 expression in mucosal CD4 T cells under
from the pBluescript phagemid by EcoRI and XhoI and subclonedinflammatory conditions.
into pGEX-6P vector (Pharmacia) to produce GST fusion proteins.Functionally, IL-6 exerts a variety of biological effects,
After protein induction in BL-21 strain with 0.1 mM IPTG, the fusion
including the generation of complicated proinflamma- proteins were purified with glutathione Sepharose 4B (Pharmacia)
tory cytokine loops (Taga and Kishimoto, 1997). In addi- and the recombinant proteins separated from the GST moiety by
using PreScission protease (Pharmacia). The purified recombinanttion, IL-6 can enhance survival of pathogenic CD4
proteins were applied to endotoxin removing gel (Pierce), dialyzedT cells (Atreya et al., 2000) and allow the presentation
to PBS, and concentrated. For 72 hr, 2  105 MLN and colonic LPof cryptic determinants (pathogenic antigens) to T cells
cells in 150 l culture medium (F12/DMEM containing 1% FBS, 1by the APC (Drakesmith et al., 1998). Indeed, acquired
SITE3 [Sigma], 10 mM sodium pyruvate, and 50 M 2-ME) were
immune responses dysregulated by enhanced IL-6 pro- cultured with various doses of recombinant protein. The culture
duction play a critical role in the development and per- supernatants were then subjected to Opti-ELISA (Pharmingen) ac-
cording to manufacturer’s instruction. The results were statisticallypetuation of T cell-mediated chronic colitis (Atreya et
analyzed using the Mann-Whitney U test.al., 2000; Yamamoto et al., 2000; Mizoguchi et al., 2002b)
as well as chemically induced acute colitis (Atreya et
Generation of mAb and Detection of Galectin-4al., 2000; Suzuki et al., 2001). In contrast, a preserved
Cells were isolated from MLN of diseased TCRKO mice without
IL-6/STAT3 cascade is required for activation of macro- immunization. The cells were fused with NS-1 myeloma cell line
phages and epithelial cells to maintain or strengthen the using polyethylene glycol (Sigma) as previously described (Mizo-
defense against enteric microorganisms. Indeed, down- guchi et al., 1997a). After selection with HAT medium, the hybrido-
mas were screened by Western blot using recombinant galectin-4,regulation of macrophage- and epithelial cell-mediated
and the positive clones were subcloned by using methylcelluroseinnate immune responses by the absence of IL-6/STAT3
medium. After production of ascites containing the Abs in RAG-1cascade can also induce intestinal inflammation
KO mice, mAbs were purified by using protein A Sepharose and
(Takeda et al., 1999; Tebbutt et al., 2002; Welte et al., dialyzed to PBS. For immunohistochemical analysis, the mAbs were
2003). Therefore, IL-6 seems to play distinctly different biotinylated by using Sulfo-NHS-LC biotin kit (Pierce). Frozen co-
roles in the innate immunity-mediated induction phase lonic tissues were stained by using an avidin-biotin complex method
using biotinylated anti-galectin-4 mAb (Mizoguchi et al., 2002b).and the acquired immunity-mediated exacerbation
phase of intestinal inflammation. In the present study,
Detection of Galectin Bindingwe demonstrate that galectin-4 contributes to not only
According to the manufacturer’s instruction, 1 mg of galectin-4 andexacerbate a T cell-mediated chronic colitis but also
galectin-3 were labeled with Alexa Fluor 488 (Molecular Probe). For
delay the recovery from acute intestinal injury by stimu- 10 min, 5  105 cells were incubated with Alexa Fluor 488-labeled
lating IL-6 production that enhances the survival of in- recombinant galectin-4 (2 g/ml) or galectin-3 (2 g/ml) at 25C,
testinal CD4 T cells. Therefore, CEC-derived galectin-4 followed by staining with PE-anti-CD4 mAb and PerCP-anti-TCR
mAb, and subjected to flow cytometric and fluorescence micro-may be an important mediator to enhance harmful ac-
scopic analysis. For confocal microscopic analysis, purified colonicquired immune responses for the exacerbation and/or
LP CD4 cells that were purified by using biotinylated anti-CD4/perpetuation of inflammation after the triggering events
streptavidin magnetic beads under MACS system were stained with
induced by acquired or innate immunity. Alexa Fluor 488-labeled recombinant galectin-4, followed by incuba-
In the present study, we provide an insight into CEC- tion with 0.2 g/ml Alexa Fluor 594-labeled cholera toxin (Molecular
derived lectin/CD4 T cell interaction, which contributes Probes) on ice for 1 min (Burack et al., 2002).
to the progression of intestinal inflammation. Blockade
Experimental Colitis Models and Disease Detectionof such interactions by the neutralization of endogenous
TCRKO, DKO, RAG-1 KO, wt mice (all are C57BL/6 background),lectins using the specific mAbs may be a useful ap-
and PKCKO mice (129/B6) (Sun et al., 2000) were maintained underproach to suppress the exacerbation of inflammation.
specific pathogen-free facilities at Massachusetts General Hospital.
The CD45RB model was produced as previously described (Read
et al., 2000; Simpson et al., 1998). For DSS-induced colitis, femaleExperimental Procedures
wt (10–12 weeks of age) mice whose body weight is ranging from
20 to 23 g were used (Williama et al., 2002). The treatment wasScreening of Immunogenic Antigens
Pure CEC were obtained from TCRKO mice with colitis by using a carried out by adding 3.5% or 4% DSS (MW: 36,000–50,000, ICN
Biomedicals) in drinking water for 5 days, and the DSS administra-30 mM EDTA perfusion method (Mizoguchi et al., 2002b). Directional
ZAP-cDNA libraries (Stratagene) were generated from 10 g mRNA tion was then terminated by changing the DSS water to normal
drinking water. To avoid the influence by degree of inflammationof the freshly isolated CEC according to the manufacturer’s instruc-
tion. Immunoglobulins (Igs) were purified from serum pooled from induction, injections of mAb or recombinant protein were carried
out into the selected mice, which showed 90%–93% of body weight200 TCRKO mice with colitis by using protein A/L beads (Pierce)
and absorbed with E. coli phage lysate (Stratagen). The CEC cDNA on day 4 compared to the initial body weight on day 0. The disease
score of chronic colitis was evaluated according to previously de-libraries were then screened by the purified Igs (Sahin et al., 1995).
Positive plaques were subjected to in vivo excision using ExAssist scribed criteria (Mizoguchi et al., 2002a). The disease score (0–12)
(J) With administration of PBS (P), galectin-4 (G4), or galectin-3 (G3), 10 g of total RNA were isolated from the colonic mucosa without an
epithelial layer (Mizoguchi et al., 1997b) of the DSS-treated mice (day 8) and subjected to RPA for detection of IL-6 mRNA.
(K and L) Colitis was induced in wt female mice by adding 3.5% DSS in drinking water. The treatment was terminated day 5 by changing the
DSS water to normal drinking water. Two milligrams of recombinant galectin-4 was intravenously injected twice on day 4 and day 6 (solid
arrows). Subsequently, these mice were intraperitoneally administrated without (G4) or with anti-IL-6 mAbs (0.75 mg/injection, MP5-20F3,
Pharmingen) (G4  @IL6, n  4) or control rat Igs (G4  C, n  4) on day 4, 6, and 8 (white arrow heads).
(K) The body weight changes (%) compared to the initial body weight (day 0) are shown. “*” represents p  0.01.
(L) These mice were sacrificed on day 14. Colonic LP cells were isolated, stained with FITC-CD4 and PE-B220 mAbs, and subjected to flow
cytometric analysis.
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of DSS colitis was estimated by gross score (0, normal appearance; membrane microdomains exist at physiological temperature: role
of galectin-4 as lipid raft stabilizer revealed by “superrafts.” J. Biol.1, focal change; 2, change in entire colon), length of colon (0, 	7.5
cm; 1, 6.5–7.5 cm; 2, 6.5 cm), occult blood (0, negative; 1, weak Chem. 278, 15679–15684.
positive; 2, strong positive) detected by Hemoccult Sensa (Beckman Burack, W.R., Lee, K.-H., Holdorf, A.D., Dustin, M.L., and Shaw, A.S.
Coulter), and histological score (inflammatory cell infiltration [0–3] (2002). Quantitative imaging of raft accumulation in the immunologi-
and epithelial cell damage [0–3]). cal synapse. J. Immunol. 169, 2837–2841.
Chung, C.D., Patel, V.P., Moran, M., Lewis, L.A., and Miceli, M.C.
RPA, RT-PCR, and Real-Time PCR (2000). Galectin-1 induced partial TCR-chain phosphorylation and
The RPA was performed using 10g of total RNA with the RiboQuant antagonizes processive TCR signal transduction. J. Immunol. 165,
multiprobe RNase protection assay system (PharMingen) as pre- 3722–3729.
viously described (Mizoguchi et al., 2002a). RT-PCR was carried
Dahl, M.R., Thiel, S., Matsushita, M., Fujita, T., Willis, A.C., Chris-out as previously described (Mizoguchi et al., 1999). cDNA was
tensen, T., Vorup-Jensen, T., and Jensenius, J.C. (2001). MASP-3synthesized using (dT)17 primer and Omniscript reverse transcriptase
and its association with distinct complexes of the mannan-binding(QIAGEN) in 20 l reaction buffer. By using the specific primer pairs
lectin complement activation pathway. Immunity 15, 127–135.for IL-6, CD4, and -actin (Mizoguchi et al., 1999), galectin-4 (F:5-
Daniels, M.A., Devine, L., Miller, J.D., Moser, J.M., Lukacher, A.E.,ACCTGGAACTTCAGTCAATCA-3 and R:5-TCCCTTGATTATGATG
Altman, J.D., Kavathas, P., Hogquist, K.A., and Jameson, S.C. (2001).GTTCT-3), bcl-2 (F:5-ATCTTCTCCTTCCAGCCTGA-3 and R:5-
CD8 binding to MHC class I molecules is influenced by T cell matura-ACCGAACTCAAAGAAGGCCA-3) and bcl-XL (F:5-CGACTTTCTC
tion and glycosylation. Immunity 15, 1051–1061.TCCTACAAGC-3 and R:5-CTGCTCAAAGCTCTGATACG-3), 0.5–1
l of cDNA reactions was amplified. For real-time PCR, the cDNA Dell, A., and Morris, H.R. (2001). Glycoprotein structure determina-
were initially amplified by using SYBR green PCR core reagent kit tion by mass spectrometry. Science 291, 2351–2356.
(Stratagene) with a primer set specific for -actin. The real-time PCR Demetriou, M., Granovsky, M., Quaggin, S., and Dennis, J.W. (2001).
reaction was carried out by MX3000p QPCR machine (Stratagene), Negative regulation of T-cell activation and autoimmunity by Mgat5
and the cDNA concentration was further normalized as the CT value N-glycosylation. Nature 409, 733–739.
of -actin represents 22 cycles. The normalized cDNA samples were
Dieleman, L.A., Ridwan, B.U., Tennyson, G.S., Beagley, K.W., Bucy,subjected to real-time PCR with rox dye as a reference dye for the
R.P., and Elson, C.O. (1994). Dextran sulfate sodium-induced colitismeasurement of expression levels of specific molecules.
occurs in severe combined immunodeficient mice. Gastroenterol-
ogy 107, 1643–1652.Acknowledgments
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